These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 19075777

  • 1. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G, Qian YW, Kowala MC, Konrad RJ.
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
    [Abstract] [Full Text] [Related]

  • 2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 3. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S, Serban MC, Banach M.
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [Abstract] [Full Text] [Related]

  • 4. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.
    Circulation; 2015 Oct 27; 132(17):1648-66. PubMed ID: 26503748
    [Abstract] [Full Text] [Related]

  • 5. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA, Elshourbagy NA, Mousa SA.
    Pharmacol Ther; 2016 Aug 27; 164():183-94. PubMed ID: 27133571
    [Abstract] [Full Text] [Related]

  • 6. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
    Poirier S, Mayer G.
    Drug Des Devel Ther; 2013 Aug 27; 7():1135-48. PubMed ID: 24115837
    [Abstract] [Full Text] [Related]

  • 7. Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.
    Banaszewska A, Piechota M, Plewa R.
    Cell Mol Biol Lett; 2012 Jun 27; 17(2):228-39. PubMed ID: 22311433
    [Abstract] [Full Text] [Related]

  • 8. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A, Simental-Mendía LE, Guerrero-Romero F, Golledge J, Watts GF.
    Diabetes Obes Metab; 2015 Nov 27; 17(11):1042-55. PubMed ID: 26183252
    [Abstract] [Full Text] [Related]

  • 9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L, Peng H, Xu D, Zhao S.
    Pharmacol Res; 2013 Jul 27; 73():27-34. PubMed ID: 23578522
    [Abstract] [Full Text] [Related]

  • 10. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.
    Konrad RJ, Troutt JS, Cao G.
    Lipids Health Dis; 2011 Feb 28; 10():38. PubMed ID: 21352602
    [Abstract] [Full Text] [Related]

  • 11. The PCSK9 decade.
    Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK.
    J Lipid Res; 2012 Dec 28; 53(12):2515-24. PubMed ID: 22811413
    [Abstract] [Full Text] [Related]

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 13. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.
    Int J Biol Sci; 2012 Oct 15; 8(3):310-27. PubMed ID: 22355267
    [Abstract] [Full Text] [Related]

  • 14. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, Wu S, Chin SM, Lee NA, Rossi A, Lin JC, Rajpal A, Pons J, Shelton DL.
    J Pharmacol Exp Ther; 2012 Feb 15; 340(2):228-36. PubMed ID: 22019884
    [Abstract] [Full Text] [Related]

  • 15. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H, Melone M, Rashid S.
    Expert Rev Cardiovasc Ther; 2014 Oct 15; 12(10):1137-44. PubMed ID: 25244623
    [Abstract] [Full Text] [Related]

  • 16. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
    Werner C, Hoffmann MM, Winkler K, Böhm M, Laufs U.
    Vascul Pharmacol; 2014 Aug 15; 62(2):94-102. PubMed ID: 24685817
    [Abstract] [Full Text] [Related]

  • 17. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 15; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 18. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T, Nakamura K, Doi M, Ito H.
    Am J Cardiovasc Drugs; 2015 Jun 15; 15(3):213-9. PubMed ID: 25896669
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D.
    Drug News Perspect; 2008 Jun 15; 21(6):323-30. PubMed ID: 18836590
    [Abstract] [Full Text] [Related]

  • 20. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ, Li JJ.
    Clin Chim Acta; 2014 Apr 20; 431():148-53. PubMed ID: 24518357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.